<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-04">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Tue Feb  4 12:46:37 2003" -->
<!-- isoreceived="20030204194637" -->
<!-- sent="Tue, 4 Feb 2003 14:56:19 -0500" -->
<!-- isosent="20030204195619" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLMEIMCJAA.rms2g@virginia.edu" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="000801c2c873$1d0709f0$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Tue Feb 04 2003 - 12:56:19 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2099.html">Rafal Smigrodzki: "RE: Hydrogen as SCAM?"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2097.html">Dehede011@aol.com: "Re: Time to ask yourself...."</a>
<li><strong>In reply to:</strong> <a href="../0301/1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2098">[ date ]</a>
<a href="index.html#2098">[ thread ]</a>
<a href="subject.html#2098">[ subject ]</a>
<a href="author.html#2098">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<em>&gt; Rafal Smigrodzki wrote:
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt; ### I know selegiline is a selective MAOI.
</em><br>
<em>&gt;&gt; I meant to write &quot;How does it compare to other MAOI's?&quot;
</em><br>
<em>&gt;&gt; In other words, since MAOI's suck, and selegiline is a MAOI,
</em><br>
<em>&gt;&gt; selegiline sucks, too.
</em><br>
<em>&gt;
</em><br>
<em>&gt; MAOI's don't &quot;suck.&quot; Were it not for the risks of hypertensive crises
</em><br>
<em>&gt; from tyramine rich foods then MAOI's would still reign supreme as the
</em><br>
<em>&gt; best and safest antidepressants in existence. It is only because of
</em><br>
<em>&gt; those hypertensive risks associated with certain foods that the
</em><br>
<em>&gt; tricyclics and SSRI's and others were developed.
</em><br>
<p>### Actually, MAOI's have all kinds of other side effects, such as
<br>
palpitations, somnolence, agitation, hypertension, headache, hepatotoxicity,
<br>
and a very, very long list of drug interactions.
<br>
<p>--------------
<br>
<p>&nbsp;But the MAOI
<br>
<em>&gt; selegiline does not suffer from those risks, Rafal, because as I've
</em><br>
<em>&gt; stated several times, at normal dosages it is a selective inhibitor
</em><br>
<em>&gt; only of *MAO-B*, and the inhibition of MAO-B does not entail any
</em><br>
<em>&gt; risks of hypertensive crises.
</em><br>
<p>### At selective doses (10mg) selegiline has insufficient potency, at
<br>
effective doses (30-60 mg) it is no longer selective enough (one of your
<br>
abstracts mentions that, too).
<br>
<p>------------
<br>
<p><em>&gt;
</em><br>
<em>&gt;&gt; Give me some data supporting the contention that selegiline is &quot;an
</em><br>
<em>&gt;&gt; excellent antidepressant&quot;, compared to the SSRI's, TCA's, and
</em><br>
<em>&gt;&gt; atypicals I mentioned above.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Okay I will offer a few of abstracts below on that subject, but as I
</em><br>
<em>&gt; wrote above this is really beside the point. I'm not interested in
</em><br>
<em>&gt; defending selegiline only as an antidepressant. Its key value to
</em><br>
<em>&gt; transhumanists and others here is that it is a potent
</em><br>
<em>&gt; neuroprotectant, a cognitive aid, and a potential agent of life
</em><br>
<em>&gt; extension.
</em><br>
<p>### &quot;Potential&quot; is the key word here. So far there is no proof of life
<br>
extension in humans, and no proof of neuroprotection in PD.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2099.html">Rafal Smigrodzki: "RE: Hydrogen as SCAM?"</a>
<li><strong>Previous message:</strong> <a href="2097.html">Dehede011@aol.com: "Re: Time to ask yourself...."</a>
<li><strong>In reply to:</strong> <a href="../0301/1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2098">[ date ]</a>
<a href="index.html#2098">[ thread ]</a>
<a href="subject.html#2098">[ subject ]</a>
<a href="author.html#2098">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Tue Feb 04 2003 - 12:48:57 MST
</em></small></p>
</body>
</html>
